Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.38 |
| ▸ | CA1 | P00915 | 11/20 | 0.38 |
| ▸ | MMP1 | P03956 | 6/20 | 0.38 |
| ▸ | MMP2 | P08253 | 6/20 | 0.38 |
| ▸ | MMP9 | P14780 | 6/20 | 0.38 |
| ▸ | MMP8 | P22894 | 6/20 | 0.38 |
| ▸ | MMP13 | P45452 | 6/20 | 0.38 |
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25394926 | 1.00 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL30067119 | 1.00 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL575405 | 0.83 | CA2 (0.40) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL4461257 | 0.83 | CA2 (0.40) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL576166 | 0.82 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL979982 | 0.82 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL575657 | 0.82 | CA2 (0.43) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL8101301 | 0.78 | F2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL27192551 | 0.78 | CA2 (0.37) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL8097700 | 0.78 | F2 (0.41) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266159-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-10-23 | — | — | EP | claimed |
| US-8277972-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2012-10-02 | — | — | US | claimed |
| US-20110008684-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG ENERGY SOLUTION, LTD. (KR) | 2011-01-13 | — | — | US | claimed |
| EP-2266159-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG Chem, Ltd. (KR) | 2010-12-29 | — | — | EP | claimed |
| WO-2009116740-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2009-09-24 | — | — | WO | claimed |
| EP-4308096-B1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4561562-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025002177-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 长春金赛药业有限责任公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20240308980-A1 | HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240190831-A1 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024026128-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-2922851-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| EP-2266159-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| US-8277972-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2012-10-02 | — | — | US | disclosed |
| US-20110008684-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG ENERGY SOLUTION, LTD. (KR) | 2011-01-13 | — | — | US | disclosed |
| EP-2266159-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG Chem, Ltd. (KR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009116740-A2 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308980-A1 | HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | CA2 4394/4885CA1 4876/4885MMP1 4849/4885 |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | CA2 3438/4885CA1 2385/4885MMP1 3743/4885 |
| US-20240190831-A1 | TRANSTHYRETIN STABILIZING COMPOUNDS | TTR, TTPA, MTPN | CA2 4172/4885CA1 4288/4885MMP1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.